Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phentolamine
Drug ID BADD_D01758
Description A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of raynaud disease and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.
Indications and Usage Used as an aid for the diagnosis of pheochromocytoma, and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor. Phentolamine has also been used to treat hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs in patients taking MAO inhibitors, or by clonidine withdrawal syndrome. Other indications include the prevention of dermal necrosis and sloughing following IV administration or extravasation of norepinephrine, decrease in impedance to left ventricular ejection and the infarct size in patients with MI associated with left ventricular failure, treatment of erectile dysfunction through self-injection of small doses combined with papaverine hydrochloride into the corpus cavernosum, and as an adjunct to the management of cocaine overdose to reverse coronary vasoconstriction following use of oxygen, benzodiazepines,and nitroglycerin.
Marketing Status approved
ATC Code C04AB01; V03AB36
DrugBank ID DB00692
KEGG ID D08362
MeSH ID D010646
PubChem ID 5775
TTD Drug ID D01JUF
NDC Product Code Not Available
UNII Z468598HBV
Synonyms Phentolamine | Fentolamin | Phentolamine Mono-hydrochloride | Mono-hydrochloride, Phentolamine | Phentolamine Mono hydrochloride | Rogitine | Z-Max | Phentolamine Mesylate | Mesylate, Phentolamine | Phentolamine Methanesulfonate | Methanesulfonate, Phentolamine | Phentolamine Mesilate | Mesilate, Phentolamine | Regitine | Regityn
Chemical Information
Molecular Formula C17H19N3O
CAS Registry Number 50-60-2
SMILES CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Angina pectoris24.04.04.002; 02.02.02.002--
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Blood pressure increased13.14.03.005--Not Available
Bradycardia02.03.02.002--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Diarrhoea07.02.01.001--
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Headache17.14.01.001--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction08.02.03.014; 12.07.03.015--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Oral pain07.05.05.034--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Pain in jaw15.02.01.003--Not Available
Paraesthesia17.02.06.005; 23.03.03.094--
Peptic ulcer07.04.07.001--Not Available
Pruritus23.03.12.001--
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages